ABOS Stock Summary and Trading Ideas (Acumen Pharmaceuticals | NASDAQ:ABOS)

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Acumen Pharmaceuticals trades on the NASDAQ stock market under the symbol ABOS.

As of August 26, 2026, ABOS stock price declined to $2.99 with 232,365 million shares trading.

ABOS has a beta of 2.04, meaning it tends to be more sensitive to market movements. ABOS has a correlation of 0.09 to the broad based SPY ETF.

ABOS has a market cap of $216.23 million. This is considered a Small Cap stock.

In the last 3 years, ABOS traded as high as $6.37 and as low as $.86.

The top ETF exchange traded funds that ABOS belongs to (by Net Assets): IWM, VTI, IWN, VXF, VTWO.

ABOS has outperformed the market in the last year with a price return of +98.0% while the SPY ETF gained +20.4%. ABOS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +19.1% and +21.1%, respectively, while the SPY returned +3.0% and -0.6%, respectively.

ABOS support price is $2.95 and resistance is $3.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABOS shares will trade within this expected range on the day.